![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, May 18, 2009 7:05:28 PM
If you look at the enterprise values attributed to small CNS companies, Cypress Biosciences, with the launch underway for Savella they partnered with Forest, has an enterprise value (not including cash) of what, about $120 million? There is a cadre of relatively well-off companies like Cephalon, Shire, Sepracor, and then there's almost everybody else, with valuations in the double digit millions--or less, even negative numbers. Cypress is one of the few in between, and XenoPort. $5 per share would mean $300+ million. The only way one can get there is to license SA/RD for enough money to operate for long enough to run whatever low impact remains available through Phase II for ADHD. That's the best-case scenario in this environment, and while it's not impossible, getting that much upfront (how much they need depends on whether they still could use CX1739, unlikely, or a backup) is a challenge given the time constraints.
It's not going to happen with a nearterm buyout, not anywhere close.
And just to raise the topic of bad luck again, I suspect that someone will suggest that it's Cortex's fault that Schering-Plough probably took itself out of partnering because of agreeing to be purchased by Merck. But that's a big card that's unlikely to be played.
Enemem: It's been discussed--patients come for two nights to assess their stability of apnea symptoms, it's the third night that the efficacy is tested. If they aren't consistent on the first two nights, it's too risky to run them through the trial.
NeuroInvestment
Recent RSPI News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 12:30:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:01:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:45:26 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM